



## **Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference**

September 25, 2023

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Chardan 7th Annual Genetic Medicines Conference in New York, NY, on October 2, 2023, at 5:30 p.m. ET.

A webcast of the presentation may be accessed from the Investors section of Voyager's website at [ir.voyagertherapeutics.com](http://ir.voyagertherapeutics.com). A replay of the webcast will be archived on the Company's website for at least 30 days.

### **About Voyager Therapeutics**

Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager's TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager's own pipeline. Voyager's pipeline includes wholly owned and collaborative preclinical programs in Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit [www.voyagertherapeutics.com](http://www.voyagertherapeutics.com).

*Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.*

### **Contacts**

#### **Investors**

[Investors@vygr.com](mailto:Investors@vygr.com)

#### **Media**

Peg Rusconi

[prusconi@vergescientific.com](mailto:prusconi@vergescientific.com)



Source: Voyager Therapeutics, Inc.